 | Up a level |
Journal Article
Wolf, J., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Robeva, A., Le Mouhaer, S., Carbini, M., Yovine, A. and Heist, R. (2022). Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1. Ann. Oncol., 33. S. S42 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Groen, H. J. M., Tan, D. S. W., Garon, E. B., Demanse, D., Robeva, A., Yovine, A., Fairchild, L., Boran, A. D. and Heist, R. (2022). Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study. Ann. Oncol., 33 (7). S. S1003 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D., Garon, E., Groen, H., Hochmair, M., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S2399 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Wolf, J., Han, J., Nishio, M., Souquet, P., Paz-Ares, L., De Marinis, F., Seto, T., De Jonge, M., Kim, T. M., Vansteenkiste, J., Tan, D. S. W., Garon, E. B., Groen, H., Hochmair, M. J., Felip, E., Reguart, N., Thomas, M., Overbeck, T., Ohashi, K., Giovannini, M., Yura, R., Joshi, A., Akimov, M. and Heist, R. (2017). GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR wt, MET-dysregulated Advanced NSCLC. J. Thorac. Oncol., 12 (11). S. S1578 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Wolf, J., Heist, R., Kim, T. M., Nishio, M., Dooms, C., Kanthala, R. R., Leo, E., Giorgetti, E., Wang, Y., Mardjuadi, F. I. and Cortot, A. (2022). Efficacy and safety of capmatinib plus spartalizumab in treatment-naive patients with advanced NSCLC harboring MET exon 14 skipping mutation. Ann. Oncol., 33 (7). S. S1007 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Hochmair, M., Kattan, J. G., Ang, M. -K., Garon, E. B., Groen, H. J. M., Heist, R., Ohashi, K., Felip, E., Reguart, N., Garcia Campelo, R., Soo, R., Paz-Ares, L., de Marinis, F., Smit, E. F., Giovannini, M., Squires, M., Cui, X., Zhang, Y. and Tan, D. (2015). A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease. Ann. Oncol., 26. S. 146 - 147. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041